[
  {
    "response": "```json\n{\n    \"question\": \"How is HIV diagnosed?\",\n    \"true_answer\": \"HIV is diagnosed through HIV testing. There are three types of tests used to diagnose HIV infection: antibody tests, antigen/antibody tests, and nucleic acid tests (NATs). How soon each test can detect HIV infection differs, because each test has a different window period. The window period is the time between when a person may have been exposed to HIV and when a test can accurately detect HIV infection. Window periods for different HIV tests are the followings: Antibody tests can usually detect HIV 23 to 90 days after exposure. Most rapid tests and self-tests are antibody tests. A rapid antigen/antibody test done with blood from a finger stick can usually detect HIV 18 to 90 days after exposure. An antigen/antibody lab test using blood from a vein can usually detect HIV 18 to 45 days after exposure. A NAT can usually detect HIV 10 to 33 days after exposure. When an HIV test is positive, a follow-up test will be conducted for confirmation. Sometimes people will need to visit a health care provider to take a follow-up test using another blood sample. Other times, the follow-up test may be performed in a lab using the original blood sample to ensure that the first positive result wasn\u2019t a false positive\",\n    \"true_answer_rephrased\": \"HIV diagnosis is achieved through serological and molecular testing methodologies. The diagnostic process involves three primary assays: serological antibody assays, combined antigen/antibody assays, and nucleic acid amplification tests (NAATs). The detection window varies among these assays due to differing seroconversion periods. The seroconversion window is the interval between potential HIV exposure and the point at which the infection can be reliably identified by a test. The detection windows for these assays are as follows: Antibody assays typically identify HIV infection between 23 to 90 days post-exposure, with most rapid and self-administered tests falling into this category. Rapid antigen/antibody assays utilizing capillary blood samples can detect HIV from 18 to 90 days post-exposure. Laboratory-based antigen/antibody assays using venous blood samples can identify HIV from 18 to 45 days post-exposure. NAATs are capable of detecting HIV from 10 to 33 days post-exposure. A confirmatory test is required following a positive result to rule out false positives. This may involve a subsequent visit to a healthcare provider for additional blood sampling or laboratory confirmation using the initial specimen.\"\n}\n```"
  },
  {
    "response": "```json\n{\n    \"question\": \"What are the different stages of HIV?\",\n    \"true_answer\": \"The different stages of HIV are either defined as three: (1) acute HIV infection, (2) chronic HIV infection, and (3) acquired immunodeficiency syndrome (AIDS); or four: (1) acute HIV infection, (2) asymptomatic stage, (3) symptomatic HIV, and (4) Late-stage HIV or AIDS.\",\n    \"true_answer_rephrased\": \"The progression of HIV can be categorized into either three stages: (1) acute HIV infection, (2) chronic HIV infection, and (3) acquired immunodeficiency syndrome (AIDS); or four stages: (1) acute HIV infection, (2) asymptomatic phase, (3) symptomatic HIV infection, and (4) advanced HIV disease or AIDS.\"\n}\n```"
  },
  {
    "response": "```json\n{\n    \"question\": \"How is HIV transmitted?\",\n    \"true_answer\": \"HIV is spread from the body fluids of an infected person, including blood, breast milk, semen and vaginal fluids. It can also spread from a mother to her baby.\",\n    \"true_answer_rephrased\": \"HIV is transmitted through the exchange of bodily fluids from an individual with the virus, such as blood, breast milk, semen, and vaginal secretions. Vertical transmission from mother to child is also possible.\"\n}\n```"
  },
  {
    "response": "```json\n{\n    \"question\": \"What comorbidities are common among people living with HIV?\",\n    \"true_answer\": \"The most common comorbidities amongst patients with HIV include: diabetes mellitus, cardiovascular disease (CVD, e.g. hypertension), respiratory diseases (e.g. chronic obstructive pulmonary diseases and pneumonia), and hepatic diseases (hepatitis B and C). Liver disease, renal disease, substance dependence and abuse, sexually transmitted infections (herpes simplex, syphilis, gonorrhoea and Mycoplasma genitalium) and psychiatric disorders (including depression, anxiety, schizophrenia and cognitive impairment) are also greater among HIV-positive individuals.\",\n    \"true_answer_rephrased\": \"Individuals diagnosed with HIV frequently present with comorbid conditions such as diabetes mellitus, cardiovascular pathologies (including hypertension), pulmonary disorders (such as chronic obstructive pulmonary disease and pneumonia), and hepatic conditions (notably hepatitis B and C). Additionally, there is an increased prevalence of hepatic and renal pathologies, substance use disorders, sexually transmitted infections (such as herpes simplex, syphilis, gonorrhea, and Mycoplasma genitalium), and psychiatric conditions (including depressive disorders, anxiety disorders, schizophrenia, and cognitive dysfunction) among those who are HIV-positive.\"\n}\n```"
  },
  {
    "response": "```json\n{\n    \"question\": \"How can HIV be prevented?\",\n    \"true_answer\": \"HIV prevention involves several key strategies. To reduce the risk of getting HIV, it is important to use condoms correctly every time during sex. For individuals who inject drugs, avoiding drug use altogether is recommended, but if drugs are used, only sterile injection equipment and water should be used, and equipment should never be shared with others. Pre-exposure prophylaxis (PrEP) is an option for those at risk of HIV, involving either a daily HIV medicine or an injectable HIV medicine every two months to lower the risk of infection through sex or injection drug use. For those already living with HIV, taking antiretroviral therapy (ART) as prescribed can reduce the amount of HIV in the blood to undetectable levels, preventing transmission to sexual partners. To prevent perinatal transmission, individuals with HIV who take HIV medicine as prescribed throughout pregnancy and childbirth reduce the risk of passing HIV to their baby to less than 1%. Additionally, in cases where one partner has HIV, PrEP can help protect both the individual and their baby while trying to conceive, during pregnancy, or while breastfeeding.\",\n    \"true_answer_rephrased\": \"HIV prophylaxis encompasses several critical interventions. Consistent and correct condom usage during sexual intercourse is essential to mitigate HIV transmission risk. For individuals who engage in intravenous drug use, complete abstinence is advised; however, if drug use occurs, it is imperative to utilize only sterile syringes and water, and to refrain from sharing injection paraphernalia. Pre-exposure prophylaxis (PrEP) is a preventive measure for individuals at elevated risk of HIV, involving either a daily antiretroviral medication or a bimonthly injectable formulation to diminish the likelihood of HIV acquisition via sexual contact or injection drug use. For individuals diagnosed with HIV, adherence to antiretroviral therapy (ART) as prescribed can suppress viral load to undetectable levels, thereby preventing sexual transmission. To avert vertical transmission, individuals with HIV who adhere to antiretroviral regimens during gestation and parturition can reduce the probability of transmitting HIV to their offspring to less than 1%. Furthermore, in serodiscordant couples, PrEP can offer protection to both the HIV-negative partner and their child during conception, pregnancy, and lactation.\"\n}\n```"
  },
  {
    "response": "```json\n{\n    \"question\": \"How frequently ART must be taken?\",\n    \"true_answer\": \"Antiretroviral therapy (ART) must be taken as a pill every day or as a shot once every month or two months.\",\n    \"true_answer_rephrased\": \"Antiretroviral therapy (ART) should be administered orally on a daily basis or via intramuscular injection at intervals of one to two months.\"\n}\n```"
  },
  {
    "response": "```json\n{\n    \"question\": \"How can we prevent Perinatal transmission of HIV?\",\n    \"true_answer\": \"To prevent perinatal transmission of HIV, pregnant women should take antiretroviral therapy (ART) throughout pregnancy and childbirth. ART throughout pregnancy and childbirth reduces the chances of perinatal transmission of HIV to less than 1%.\",\n    \"true_answer_rephrased\": \"To mitigate the risk of vertical transmission of HIV, it is essential for expectant mothers to adhere to antiretroviral therapy (ART) during the entire gestational period and delivery. Consistent ART administration during these stages can decrease the likelihood of HIV transmission from mother to child to below 1%.\"\n}\n```"
  },
  {
    "response": "```json\n{\n    \"question\": \"What are the main cell types infected with HIV?\",\n    \"true_answer\": \"The main cell types found to be infected with HIV are CD4+ T lymphocytes and macrophage-lineage cells.\",\n    \"true_answer_rephrased\": \"The primary cellular targets of HIV infection are CD4-positive T lymphocytes and cells of the macrophage lineage.\"\n}\n```"
  },
  {
    "response": "```json\n{\n    \"question\": \"What is the difference between HIV and AIDS?\",\n    \"true_answer\": \"HIV stands for human immunodeficiency virus, which is the virus that causes HIV infection. AIDS stands for acquired immunodeficiency syndrome, the most advanced stage of HIV infection.\",\n    \"true_answer_rephrased\": \"HIV refers to the human immunodeficiency virus, the pathogen responsible for initiating HIV infection. AIDS, or acquired immunodeficiency syndrome, represents the terminal phase of HIV infection.\"\n}\n```"
  },
  {
    "response": "```json\n{\n    \"question\": \"How is HIV not transmitted?\",\n    \"true_answer\": \"You cannot get HIV from: Air or water. Saliva, tears, sweat, feces, or urine that is not mixed with the blood of a person with HIV. Casual contact with a person who has HIV, such as a handshake, a hug, or a closed-mouth kiss. Contact with objects, such as toilet seats, doorknobs, or dishes used by a person who has HIV. Mosquitoes, ticks, or other biting insects. Other sexual activities that do not involve the exchange of body fluids (for example, touching). HIV can\u2019t be passed through healthy, unbroken skin.\",\n    \"true_answer_rephrased\": \"HIV is not transmitted through airborne or waterborne routes. It is not spread via saliva, tears, sweat, feces, or urine unless these fluids are contaminated with the blood of an HIV-positive individual. Transmission does not occur through casual physical interactions such as handshakes, hugs, or closed-mouth kisses. Contact with inanimate objects like toilet seats, doorknobs, or utensils used by an HIV-positive person does not facilitate transmission. Additionally, HIV is not transmitted by mosquitoes, ticks, or other hematophagous insects. Non-fluid-exchanging sexual activities, such as touching, do not result in transmission. The virus cannot penetrate intact, healthy skin.\"\n}\n```"
  },
  {
    "response": "```json\n{\n    \"question\": \"What is known about the switch that occurs between patients with latent HIV and active infection?\",\n    \"true_answer\": \"The switch between latent and active HIV infection is primarily driven by the activation of HIV provirus within latently infected cells. Latent HIV infection occurs when the virus integrates its genetic material into the host cell's DNA, allowing the virus to persist in a dormant state. In latent infection, viral replication and gene expression are minimal or absent, and the infected cells remain functionally normal. This form of infection is responsible for the long-term persistence of HIV in individuals, even when systemic viral replication is suppressed with antiretroviral therapy (ART). The switch to active HIV infection occurs when the provirus becomes transcriptionally active; this is often triggered by extracellular signals or events that activate the host cell. One possible mechanism for the switch involves the binding of cellular transcription factors, such as nuclear factor kappa B (NF-\u03baB) and nuclear factor of activated T-cells (NFAT), to the HIV long terminal repeat (LTR) region, resulting in the activation of proviral transcription. Other factors that can contribute to the switch include cytokines, chemokines, and cellular activation signals. This transition between latent and active HIV infection plays a critical role in the pathogenesis of the disease, as it is during periods of active infection that the virus replicates and spreads to new cells, ultimately leading to the progressive decline of the host immune system. Understanding the molecular mechanisms involved in the switch from latent to active HIV infection could help inform the development of novel therapeutic strategies aimed at targeting and eliminating latently infected cells, which represent a major obstacle to achieving a cure for HIV.\",\n    \"true_answer_rephrased\": \"The transition from latent to active HIV infection is predominantly mediated by the reactivation of the HIV provirus within cells harboring latent infection. Latency is characterized by the integration of viral genetic material into the host genome, maintaining the virus in a quiescent state. During latency, viral replication and gene expression are significantly reduced or absent, and the infected cells retain normal functionality. This latent state is crucial for the chronic persistence of HIV in patients, even when systemic viral replication is controlled by antiretroviral therapy (ART). The shift to active infection occurs when the provirus is transcriptionally reactivated, often initiated by external stimuli or events that activate the host cell. A potential mechanism for this reactivation involves the interaction of cellular transcription factors, such as nuclear factor kappa B (NF-\u03baB) and nuclear factor of activated T-cells (NFAT), with the HIV long terminal repeat (LTR) region, leading to the initiation of proviral transcription. Additional contributors to this switch include cytokines, chemokines, and cellular activation signals. This transition is pivotal in the disease's pathogenesis, as active infection phases facilitate viral replication and dissemination to new cells, ultimately causing the progressive deterioration of the host's immune system. Elucidating the molecular pathways governing the switch from latent to active HIV infection could guide the development of innovative therapeutic approaches aimed at eradicating latently infected cells, which pose a significant barrier to achieving an HIV cure.\"\n}\n```"
  }
]